Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
about
Effects of beta-hydroxy-beta-methylbutyrate (HMB) on exercise performance and body composition across varying levels of age, sex, and training experience: A reviewSystematic analysis of the associations between adverse drug reactions and pathwaysMuscular effects of statins in the elderly female: a reviewPreclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)Drug-induced acute myocardial infarction: identifying 'prime suspects' from electronic healthcare records-based surveillance systemSirolimus in pediatric renal transplantation.Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications.Hepatitis, rhabdomyolysis and multi-organ failure resulting from statin useStatin-induced myopathy: the two faces of Janus.Mechanisms and assessment of statin-related muscular adverse effects.The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase.Small G proteins as novel therapeutic targets in cardiovascular medicine.The toxicology of HMG-CoA reductase inhibitors: prediction of human risk.Intensive lipid-lowering therapy in patients with coronary heart disease.Current statins show calcium channel blocking activity through voltage gated channels.Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic PatientsThe role of acid-base imbalance in statin-induced myotoxicityMolecular basis for statin-induced muscle toxicity: implications and possibilities.Rhabdomyolysis a result of azithromycin and statins: an unrecognized interactionClinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network.Atorvastatin: safety and tolerability.Drug-drug interactions that interfere with statin metabolism.Association between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database.β-Hydroxy-β-methylbutyrate, mitochondrial biogenesis, and skeletal muscle health.Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia.Acute myopathy following intra-muscular injection of compound betamethasone: A case report.Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives.Differential association between statin exposure and elevated levels of creatine kinase.Muscle symptoms associated with statins: a series of twenty patients.McArdle disease with rhabdomyolysis induced by rosuvastatin: case report.A new mitochondria-related disease showing myopathy with episodic hyper-creatine kinase-emia.Skeletal muscle susceptibility to clofibrate induction of lesions in rats.Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress.Effect of simvastatin on passive strain-induced skeletal muscle injury in rats.
P2860
Q21245067-6BC5B064-00F4-47C4-85C9-5ED04DB68E64Q26779991-5B8C5268-9C96-41F2-A56D-4B9E1F78A6CEQ27023343-91DBDA17-FB2C-4396-8108-AF29C599410EQ27487391-4C80952C-BF00-41D7-933A-DCB39B6C61D4Q28535919-6ADD5A34-20B4-453F-88A0-EB8A33F889AAQ33397668-1FB95289-8BA8-45F2-8D2C-923FA3E2906AQ34155702-C064530D-DA15-4EED-88EF-70ECBF1ACF73Q34527445-1B013604-69C9-45DB-A30C-1D431BF1D6A4Q34554637-915E717E-F7B7-4214-BEAD-49ADF434B47BQ34570995-38FB35B3-66F7-4BE4-8548-B07167DA7751Q34631971-14176AEA-C45A-4819-8AF0-5015B152A302Q35017735-8E288622-4284-4DE7-981F-8DB8D0B3292BQ35047323-F0A910C7-895C-4561-9BAE-01F8734B0AD9Q35927194-39FD5D01-BBCE-42DA-8ACF-A264C40585C0Q35991019-CE01E315-5D66-4073-8D4B-00CE0D47EF27Q36138704-79089C3B-6D6D-4E00-A938-D069FFA657D7Q36637890-DEEBE82A-5ACD-401A-B22D-CF84B68AC24FQ37140174-C8F1B122-1656-41D4-86F2-D4E126CD25B9Q37235648-27781DED-2558-45AD-B34A-1BE093458AC1Q37397811-59831E0A-DFCB-492A-9FA3-CCFEB6FD30D4Q37473382-708881E1-9453-4A33-B0D5-A0CFA980CD08Q37765562-5220DD03-462D-48E8-B317-939A181C94C1Q38522299-4DCE48B6-903C-4421-936C-6813D1543738Q38613096-40747A46-52D0-49E7-BDEA-24C39005DEA4Q38634775-9EE8FCFF-1ED4-4E3D-94BD-29C5840EB48EQ38663481-0B1FB627-83C0-4C39-96BD-8D0C75B9C0D6Q41523663-66756251-0FA3-48CD-A429-5131BF84A564Q44739535-AD4DDC1A-7C3D-464C-8E1F-DD05676403D3Q46701148-359690F1-D68D-4DF2-9EFF-F7D7407BEF33Q46909422-20C5CAE0-694B-4251-900E-4D8C3CB03B3EQ46938582-DB33DC0E-5DDA-481A-885B-E9275A4E1868Q50526524-0194386F-1A16-45E7-805E-15CF2292AC1DQ50691921-C05194C4-F49C-474D-B9C0-08FD9561DF65Q53224987-F6F2C281-F15A-4F4D-9B27-6398F316D465Q54479293-17AE6813-E6E7-4D93-A948-56E25EE80130
P2860
Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
@ast
Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
@en
Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
@nl
type
label
Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
@ast
Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
@en
Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
@nl
prefLabel
Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
@ast
Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
@en
Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
@nl
P1433
P1476
Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
@en
P2093
P304
P356
10.2165/00002018-200225090-00004
P577
2002-01-01T00:00:00Z
P6179
1049897917